Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Liabilities (2016 - 2025)

Vistagen Therapeutics' Total Liabilities history spans 12 years, with the latest figure at $14.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 26.38% year-over-year to $14.1 million; the TTM value through Dec 2025 reached $14.1 million, up 26.38%, while the annual FY2025 figure was $14.0 million, 48.94% up from the prior year.
  • Total Liabilities for Q4 2025 was $14.1 million at Vistagen Therapeutics, down from $14.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $19.8 million in Q3 2021 and bottomed at $6.6 million in Q3 2023.
  • The 4-year median for Total Liabilities is $11.2 million (2024), against an average of $12.1 million.
  • The largest YoY upside for Total Liabilities was 55.29% in 2021 against a maximum downside of 31.71% in 2021.
  • A 4-year view of Total Liabilities shows it stood at $10.6 million in 2021, then fell by 26.28% to $7.8 million in 2023, then soared by 43.71% to $11.2 million in 2024, then grew by 26.38% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Total Liabilities are $14.1 million (Q4 2025), $14.6 million (Q3 2025), and $12.2 million (Q2 2025).